Centre for Design and Synthesis of Molecularly Targeted Radiopharmaceuticals (CERAD)
2017.12.14 - Marek Pawłowski The Cracow-based CP OK2 Sp. z o.o. company has won EU tender proceedings to build in Świerk a centre for design and synthesis of new molecularly targeted drugs (CERAD). The company has signed the contract to build the facility before July 2021. Facility equipment will include a modern proton/deuteron/alpha particle cyclotron dedicated to produce radioisotopes.